News and Press Releases
PADCEVTM (enfortumab vedotin) in Combination with Keytruda (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Patients with Resectable Muscle-Invasive Bladder Cancer who are Ineligible for Cisplatin-Based Chemotherapy
Positive opinion is based on data from the pivotal Phase 3 EV-303 trial showing a 60% reduction in the risk of disease recurrence, progression or death and a 50% reduction...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression 22 May 2026 -- Cambridge, UK -- STORM Therapeutics, the...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026
Pivotal trial data for EP0031 (A400), a next-generation Selective RET Inhibitor (SRI), in RET positive advanced NSCLC, to be presented at ASCO 2026
22 May 2026 -- London, UK -- Ellipses Pharma, a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study 21 May 2026 -- Hong Kong, Shanghai and New Jersey,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2026
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors Study to evaluate tertiary...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 19, 2026
Suite 15 Science Village, Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL UK
VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform
Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics, supporting the FDA’s push toward more predictive, human-relevant testing and reduced reliance on animal...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2026
Emerson Introduces Next-Generation Industrial Data Fabric, Providing Foundation for Highly Integrated Industrial Data Platform
Enhanced AspenTech Inmation OT Data Fabric to accelerate enterprise-scale intelligence 13 May 2026 -- Texas, US -- Global automation leader Emerson today announced major advancements to the AspenTech Inmation™ OT...
Category: Biotechnology, Other, Pharmaceutical
Posted: May 13, 2026
Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
The two companies are broadening their partnership, building on strong results seen in the initial phase which demonstrated e-Lung’s potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF) Findings...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
AOP Health and VRG Therapeutics Enter Co-Development Partnership for New Immunology Program
12 May 2026 -- Vienna, Austria and Budapest, Hungary -- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
Vibra to Support Expansion of MindMaze Therapeutics’ Neurorehabilitation Platform across Leading U.S. Health Systems 12 May 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
New Emerson Industrial AI Platform Delivers Enterprise-Scale AI
AspenTech AVA enables customers to act faster, develop more informed strategies, improve operational reliability 11 May 2026 -- Missouri, US -- Global automation leader Emerson today introduced the AspenTech AVA AI platform,...
Category: Logistics, Other
Posted: May 11, 2026
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.
Collaboration targets large provider groups to accelerate adoption of MindMaze Therapeutics’ evidence-based neurotherapeutic platform 30 April 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Other, Pharmaceutical
Posted: April 30, 2026
Awen Oncology secures significant new funds to advance pioneering cancer therapeutics
23 April 2026 -- Anglesey, UK -- Awen Oncology, a pioneering Wales-based therapeutics company developing next-generation cancer treatments, has secured funds from a number of sources, worth seven figures, which...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2026
Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026
Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026
Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions
Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026
